After generic defense fails, Merck KGaA assumes no US Mavenclad sales after March

5th March 2026 Uncategorised 0

After delivering solid sales growth in a difficult 2025, Germany’s Merck KGaA may have a tougher go of things this year, which the company is crediting in part to a predicted onslaught of U.S. generics to its multiple sclerosis blockbuster Mavenclad.

More: After generic defense fails, Merck KGaA assumes no US Mavenclad sales after March
Source: fierce